June 28, 2024Open Access
Multiple myeloma: 2024 update on diagnosis, risk‐stratification, and management
Key Points
Key points are not available for this paper at this time.
Abstract
A triplet regimen is usually needed at relapse, with the choice of regimen varying with each successive relapse. Chimeric antigen receptor T (CAR-T) cell therapy and bispecific antibodies are additional options.
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Authors
S. Vincent Rajkumar
University of Maryland, Baltimore
Journals
American Journal of Hematology
Actions
Institutions
Mayo Clinic
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...